In addition, NAMPT inhibitors potentiated the efficacy of the radionuclide 177Lu-DOTATATE in neuroendocrine tumors [147], and sensitized head and neck cancer and prostate cancer models to radiotherapy [186,187]. Here, NAMPT is linked to prostate carcinoma.